The renin-angiotensin and the kallikrein-kinin systems

International Journal of Biochemistry and Cell Biology

Volumn 35, Issue 6, 2003, Pages 784-791

  Campbell, Duncan J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Angiotensin; Bradykinin; Kallidin; Kallikrein; Kallistatin; Kininogen

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II [3-8]; ANGIOTENSIN III; ANGIOTENSIN RECEPTOR; ANGIOTENSIN[1-7]; BRADYKININ; BRADYKININ B1 RECEPTOR; BRADYKININ B2 RECEPTOR; BRADYKININ[1-8]; CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE; KALLIDIN; KALLIDIN[1-9]; NITRIC OXIDE SYNTHASE;

KALLIKREIN KININ SYSTEM; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN METABOLISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 0037409312     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-2725(02)00262-5     Document Type: Short Survey

References (32)

1. Celerier J., Cruz A., Lamande N., Gasc J.M., Corvol P. Angiotensinogen and its cleaved derivatives inhibit angiogenesis. Hypertension. 39:2002;224-228.
2. D.J. Campbell, Bioactive angiotensin peptides other than angiotensin II, in: M. Epstein, H.R. Brunner (Eds.), Angiotensin II Receptor Antagonists, Hanley and Belfus Inc., Philadelphia, 2001, pp. 9-27.
3. 1 ) receptor function. Regul. Pept. 79:1999;9-23.
4. Thomas W.G., Brandenburger Y., Autelitano D.J., Pham T., Qian H., Hannan R.D. Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor. Circ. Res. 90:2002;135-142.
5. Kagiyama S., Eguchi S., Frank G.D., Inagami T., Zhang Y.C., Phillips M.I. Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. Circulation. 106:2002;909-912.
6. 1 receptor antagonist. J. Biol. Chem. 276:2001;39721-39726.
7. 4 ) receptor is the enzyme insulin-regulated aminopeptidase. J. Biol. Chem. 276:2001;48623-48626.
8. Tipnis S.R., Hooper N.M., Hyde R., Karran E., Christie G., Turner A.J. A human homolog of angiotensin-converting enzyme: cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem. 275:2000;33238-33243.
9. Duncan A.M., James G.M., Anastasopoulos F., Kladis A., Briscoe T.A., Campbell D.J. Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels. J. Pharmacol. Exp. Ther. 289:1999;295-303.
10. Richards A.M., Wittert G.A., Espiner E.A., Yandle T.G., Ikram H., Frampton C. Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. Circ. Res. 71:1992;1501-1507.
11. Yanai K., Saito T., Kakinuma Y., Kon Y., Hirota K., Taniguchi-Yanai K., Nishijo N., Shigematsu Y., Horiguchi H., Kasuya Y., Sugiyama F., Yagami K., Murakami K., Fukamizu A. Renin-dependent cardiovascular functions and renin-independent blood-brain barrier functions revealed by renin-deficient mice. J. Biol. Chem. 275:2000;5-8.
12. Niimura F., Labosky P.A., Kakuchi J., Okubo S., Yoshida H., Oikawa T., Ichiki T., Naftilan A.J., Fogo A., Inagami T., Hogan B.L.M., Ichikawa I. Gene targeting in mice reveals a requirement for angiotensin in the development and maintenance of kidney morphology and growth factor regulation. J. Clin. Invest. 96:1995;2947-2954.
13. Tsuchida S., Matsusaka T., Chen X.M., Okubo S., Niimura F., Nishimura H., Fogo A., Utsunomiya H., Inagami T., Ichikawa L. Murine double nullizygotes of the angiotensin type 1A and 1B receptor genes duplicate severe abnormal phenotypes of angiotensinogen nullizygotes. J. Clin. Invest. 101:1998;755-760.
14. Yousef G.M., Diamandis E.P. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocrinol. Rev. 22:2001;184-204.
15. Takano M., Horie M., Narahara M., Miyake M., Okamoto H. Expression of kininogen mRNAs and plasma kallikrein mRNA by cultured neurons, astrocytes and meningeal cells in the rat brain. Immunopharmacology. 45:1999;121-126.
16. Bhoola K.D., Figueroa C.D., Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol. Rev. 44:1992;1-80.
17. Campbell D.J. The kallikrein-kinin system in humans. Clin. Exp. Pharmacol. Physiol. 28:2001;1060-1065.
18. Hecquet C., Tan F., Marcic B.M., Erdos E.G. Human bradykinin B(2) receptor is activated by kallikrein and other serine proteases. Mol. Pharmacol. 58:2000;828-836.
19. 1 receptor for therapeutic neovascularization. Circulation. 105:2002;360-366.
20. 2 receptor with endothelial nitric-oxide synthase. J. Biol. Chem. 273:1998;24025-24029.
21. Armstrong P.W., Lorell B.H., Nissen S., Borer J. Omapatrilat. Circulation. 106:2002;e9011-e9012.
22. Raab A., Kemme M. High molecular weight kininogen is a binding protein for tissue prokallikrein. FEBS Lett. 467:2000;165-168.
23. Schmaier A.H. Plasma kallikrein-kinin system: a revised hypothesis for its activation and its physiologic contributions. Curr. Opin. Hematol. 7:2000;261-265.
24. Nussberger J., Cugno M., Amstutz C., Cicardi M., Pellacani A., Agostoni A. Plasma bradykinin in angio-oedema. Lancet. 351:1998;1693-1697.
25. Trabold F., Pons S., Hagege A.A., Bloch-Faure M., Alhenc-Gelas F., Giudicelli J.F., Richer-Giudicelli C., Meneton P. Cardiovascular phenotypes of kinin B2 receptor- and tissue kallikrein-deficient mice. Hypertension. 40:2002;90-95.
26. Schalekamp M.A.D.H., Derkx F.H.M. Plasma kallikrein and plasmin as activators of prorenin: links between the renin-angiotensin system and other proteolytic systems in plasma. Clin. Sci. 61:1981;15-21.
27. Santos R.A.S., Passaglio K.T., Pesquero J.B., Bader M., Simoes e Silva A.C. Interactions between angiotensin-(1-7), kinins, and angiotensin II in kidney and blood vessels. Hypertension. 38:2001;660-664.
28. Marcic B.M., Erdos E.G. Protein kinase C and phosphatase inhibitors block the ability of angiotensin I-converting enzyme inhibitors to resensitise the receptor to bradykinin without altering the primary effects of bradykinin. J. Pharmacol. Exp. Ther. 294:2000;605-612.
29. 1 -receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature. 407:2000;94-98.
30. 1 receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat. Med. 7:2001;1003-1009.
31. Liu Y.H., Yang X.P., Sharov V.G., Nass O., Sabbah H.N., Peterson E., Carretero O.A. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure - role of kinins and angiotensin II type 2 receptors. J. Clin. Invest. 99:1997;1926-1935.
32. 2 receptor-dependent vasodilation is mediated by activation of vascular kinin generation under flow conditions. Br. J. Pharmacol. 136:2002;484-491.